A Pragmatic Guide to Assessing Real Option Value for Medical Technologies
Authors:
Open Access
- 22 June 2022
- journal article
- research article
- Published by Elsevier in Value in Health
- Vol. 25 (11) , 1878-1884
Abstract
No abstract availableKeywords
Funding Information
- Genentech
This publication has 19 references indexed in Scilit:
- Defining Elements of Value in Health Care—A Health Economics Approach: An ISPOR Special Task Force Report [3]Value in Health, 2018
- Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung CancerNew England Journal of Medicine, 2017
- Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness AnalysesJAMA, 2016
- Performance Status in Patients With CancerJAMA Oncology, 2015
- Hepatitis C treatment: Back to the warehouseClinical Liver Disease, 2015
- Pricing in the Market for Anticancer DrugsJournal of Economic Perspectives, 2015
- The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990sHealth Economics, 2004
- Recommendations of the Panel on Cost-Effectiveness in Health and MedicineJAMA, 1996
- Discovery and development of new antibiotics: the problem of antibiotic resistanceAntimicrobial Agents and Chemotherapy, 1993
- Determinants of corporate borrowingJournal of Financial Economics, 1977